Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Legal Services Should Be a Component of Standard Cancer Care

March 1, 2007
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

It is commonly accepted that nonmedical issues, such as loss of benefits, employment concerns, and debt management, may negatively impact the outcomes of patients fighting cancer.

NEW YORK—It is commonly accepted that nonmedical issues, such as loss of benefits, employment concerns, and debt management, may negatively impact the outcomes of patients fighting cancer. According to a recent survey co-funded by the Lance Armstrong Foundation and the Centers for Disease Control and Prevention (CDC), access to legal assistance should be part of the continuum of cancer care.

The survey was conducted by LegalHealth, a division of the New York Legal Assistance Group, which provides free legal assistance to low-income seriously ill individuals (www.legalhealth.org). "The CDC has indicated that legal service is one of the first things HIV-infected people need. And our survey shows that the same is true for cancer patients," Randye Retkin, director of LegalHealth, told ONI.

LegalHealth worked with law students, a professional nonprofit evaluator, and a public health researcher to create and administer the survey, which queried 51 cancer patients (age 29 to 82) who had been assisted by LegalHealth. The survey asked whether legal services helped reduce their worries, how it affected their financial situation and their loved ones, and if it helped them maintain their treatment regimens.

Ms. Retkin said that the financial implications of cancer left many of these patients in extremely vulnerable situations, struggling to continue working despite their illness or having to deal with the loss of a job. "Perhaps the most compelling statistic was that 78% of the individuals surveyed said that their diagnosis of cancer actually created their legal difficulties," she said. The study also found that 83% said legal services helped reduce stress, 51% said the services had a positive effect on their financial situation, and 33% reported that legal services helped their families or loved ones. "Many of our clients were just keeping their heads above water, but after a cancer diagnosis, their legal and financial situations spiraled out of control," Ms. Retkin said. Patients also said that legal services helped them keep medical appointments (22%) and maintain their treatment regimens (23%).

LegalHealth attorneys hold weekly or monthly legal clinics in New York City hospitals and community-based facilities, six of which focus on cancer. In 2006, they assisted approximately 2,300 patients, 600 of whom were diagnosed with cancer. "Our educational program trains physicians to understand the legal issues affecting their patients, and we also provide consumer training to help patients cope with potential legal issues," she said.

Along with hospitals and community facilities, LegalHealth also partners with educational and advocacy groups such as CancerCare, Inc. "We provide a monthly on-site clinic at CancerCare, working directly with cancer patients. We have a great relationship with CancerCare. They've become a big source of referrals for us," Ms. Retkin said.

Articles in this issue

Peptide-Based Breast Ca Vaccines Promising in Early Trials
Diagnostic Dilemma: GI Disease
Imatinib Responses in CML May Take Time
IV Vidaza Approved; Oral Formulation to Be Tested
Study Confirms Avastin Advantage in Advanced NSCLC
Legal Services Should Be a Component of Standard Cancer Care
Mouse Virus Evidence Suggests Viral Basis for Breast Ca
Groups Oppose Ruling on Access to Experimental Drugs
Satellite Allows Digital Mammography Screening for Rural Native Americans
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
H&N Ca Patients With CR to CRT May Not Need Surgery
Two Sets of Researchers Find Herceptin Cost Effective
Family-Based Testing Strategy May Better Detect HNPCC
More 'Promacs,' Worse Outcome
Brachytherapy Balloon Can Be Placed After Final Pathology
Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
4 experts are featured in this series.
4 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
Related Content
Advertisement

Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.

Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC

Roman Fabbricatore
October 31st 2025
Article

Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Tim Cortese
October 31st 2025
Article

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

American Society for Transplantation and Cellular Therapy
October 31st 2025
Article

Researchers have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and clinically active for adults with relapsed B-ALL following allogeneic transplant.


Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

Related Content
Advertisement

Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.

Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC

Roman Fabbricatore
October 31st 2025
Article

Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.

Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

Tim Cortese
October 31st 2025
Article

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

American Society for Transplantation and Cellular Therapy
October 31st 2025
Article

Researchers have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and clinically active for adults with relapsed B-ALL following allogeneic transplant.


Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.